Literature DB >> 15383678

Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding.

Mark R Macbeth1, Arunth T Lingam, Brenda L Bass.   

Abstract

Adenosine deaminases that act on RNA (ADARs) catalyze adenosine to inosine conversion in RNA that is largely double stranded. Human ADAR2 (hADAR2) contains two double-stranded RNA binding motifs (dsRBMs), separated by a 90-amino acid linker, and these are followed by the C-terminal catalytic domain. We assayed enzymatic activity of N-terminal deletion constructs of hADAR2 to determine the role of the dsRBMs and the intervening linker peptide. We found that a truncated protein consisting of one dsRBM and the deaminase domain was capable of deaminating a short 15-bp substrate. In contrast, full-length hADAR2 was inactive on this short substrate. In addition, we observed that the N terminus, which was deleted from the truncated protein, inhibits editing activity when added in trans. We propose that the N-terminal domain of hADAR2 contains sequences that cause auto-inhibition of the enzyme. Our results suggest activation requires binding to an RNA substrate long enough to accommodate interactions with both dsRBMs. Copyright 2004 RNA Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383678      PMCID: PMC1370643          DOI: 10.1261/rna.7920904

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  30 in total

1.  A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR.

Authors:  S Nanduri; F Rahman; B R Williams; J Qin
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

2.  Chimeric double-stranded RNA-specific adenosine deaminase ADAR1 proteins reveal functional selectivity of double-stranded RNA-binding domains from ADAR1 and protein kinase PKR.

Authors:  Y Liu; M Lei; C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 3.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

4.  Analysis of the RNA-editing reaction of ADAR2 with structural and fluorescent analogues of the GluR-B R/G editing site.

Authors:  O M Stephens; H Y Yi-Brunozzi; P A Beal
Journal:  Biochemistry       Date:  2000-10-10       Impact factor: 3.162

5.  A modular set of prokaryotic and eukaryotic expression vectors.

Authors:  K Melcher
Journal:  Anal Biochem       Date:  2000-01-01       Impact factor: 3.365

6.  The role of binding domains for dsRNA and Z-DNA in the in vivo editing of minimal substrates by ADAR1.

Authors:  A Herbert; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-09       Impact factor: 11.205

7.  The importance of internal loops within RNA substrates of ADAR1.

Authors:  K A Lehmann; B L Bass
Journal:  J Mol Biol       Date:  1999-08-06       Impact factor: 5.469

8.  Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2.

Authors:  S Sato; S K Wong; D W Lazinski
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  RNA hairpins in noncoding regions of human brain and Caenorhabditis elegans mRNA are edited by adenosine deaminases that act on RNA.

Authors:  Daniel P Morse; P Joseph Aruscavage; Brenda L Bass
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-04       Impact factor: 11.205

10.  Adenosine to inosine editing by ADAR2 requires formation of a ternary complex on the GluR-B R/G site.

Authors:  Dominic C J Jaikaran; Cynthia H Collins; Andrew M MacMillan
Journal:  J Biol Chem       Date:  2002-08-05       Impact factor: 5.157

View more
  35 in total

1.  A transition state analogue for an RNA-editing reaction.

Authors:  Brittany L Haudenschild; Olena Maydanovych; Eduardo A Véliz; Mark R Macbeth; Brenda L Bass; Peter A Beal
Journal:  J Am Chem Soc       Date:  2004-09-15       Impact factor: 15.419

Review 2.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

3.  A zipcode unzipped.

Authors:  Michael Doyle; Michael A Kiebler
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

Review 4.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

5.  Substrate-dependent contribution of double-stranded RNA-binding motifs to ADAR2 function.

Authors:  Ming Xu; K Sam Wells; Ronald B Emeson
Journal:  Mol Biol Cell       Date:  2006-05-03       Impact factor: 4.138

6.  Dimerization of ADAR2 is mediated by the double-stranded RNA binding domain.

Authors:  Hanne Poulsen; Rasmus Jorgensen; Anders Heding; Finn C Nielsen; Bjarne Bonven; Jan Egebjerg
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

Review 7.  RNA-binding proteins: modular design for efficient function.

Authors:  Bradley M Lunde; Claire Moore; Gabriele Varani
Journal:  Nat Rev Mol Cell Biol       Date:  2007-06       Impact factor: 94.444

8.  Synthesis and evaluation of an RNA editing substrate bearing 2'-deoxy-2'-mercaptoadenosine.

Authors:  Prasanna Jayalath; Subhash Pokharel; Eduardo Véliz; Peter A Beal
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-02       Impact factor: 1.381

Review 9.  How do ADARs bind RNA? New protein-RNA structures illuminate substrate recognition by the RNA editing ADARs.

Authors:  Justin M Thomas; Peter A Beal
Journal:  Bioessays       Date:  2017-02-20       Impact factor: 4.345

10.  The structure of yeast glutaminyl-tRNA synthetase and modeling of its interaction with tRNA.

Authors:  Thomas D Grant; Joseph R Luft; Jennifer R Wolfley; Mary E Snell; Hiro Tsuruta; Stephanie Corretore; Erin Quartley; Eric M Phizicky; Elizabeth J Grayhack; Edward H Snell
Journal:  J Mol Biol       Date:  2013-04-10       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.